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Hepatocyte growth factor in renal failure: Promise and reality. possible therapeutic applications of hepatocyte growth
Can science discover some secrets of Greek mythology? In the factor (HGF) and its receptor, c-met [3–5].
case of Prometheus, we can now suppose that his amazing
hepatic regeneration was caused by a peptide growth factor
called hepatocyte growth factor (HGF). Increasing evidence HEPATOCYTE GROWTH FACTOR/SCATTER
indicates that HGF acts as a multifunctional cytokine on differ- FACTOR STRUCTURE AND SYNTHESIS
ent cell types. This review addresses the molecular mechanisms
The biological features of HGF are summarized inthat are responsible for the pleiotropic effects of HGF. HGF
Table 1. Previous studies described several mitogenic andbinds with high affinity to its specific tyrosine kinase receptor
motogenic polypeptides that were identified later as HGFc-met, thereby stimulating not only cell proliferation and differ-
entiation, but also cell migration and tumorigenesis. The three [6–9]. Independently, the existence of a polypeptide se-
fundamental principles of medicine—prevention, diagnosis, creted by embryonic fibroblasts was reported that promotes
and therapy—may be benefited by the rational use of HGF. In the scattering of Madin-Darby canine kidney (MDCK)
renal tubular cells, HGF induces mitogenic and morphogenetic and other epithelial cells by paracrine mechanisms
responses. In animal models of toxic or ischemic acute renal
[10–12]. This polypeptide was named scatter factor (SF)failure, HGF acts in a renotropic and nephroprotective manner.
[13] and was later on identified as HGF [14–18]. Simulta-HGF expression is rapidly up-regulated in the remnant kidney
neously, fibroblast tumor cytotoxic factor (F-TCF) [19]of nephrectomized rats, inducing compensatory growth. In a
and the broad spectrum mitogen produced by lung fi-mouse model of chronic renal disease, HGF inhibits the pro-
gression of tubulointerstitial fibrosis and kidney dysfunction. broblasts [20] were also found to be identical to HGF.
Increased HGF mRNA transcripts were detected in mesenchy- The human HGF gene is localized on chromosome bands
mal and tubular epithelial cells of rejecting kidney. In trans- 7q11.2-21 [14]. The HGF gene promoter contains posi-
planted patients, elevated HGF levels may indicate renal rejec- tive and negative regulatory elements and is highly con-
tion. When HGF is considered as a therapeutic agent in human
served among human and rodent species [21]. Nativemedicine, for example, to stimulate kidney regeneration after
HGF is secreted as an inactive precursor (pro-HGF),acute injury, strategies need to be developed to stimulate cell
which is converted to the active form after extracellularregeneration and differentiation without an induction of tumor-
igenesis. proteolysis by several activators [22–25] and in response
to tissue injury [26]. HGF activation could be inhibited
by a specific serine protease inhibitor [27].
It has been suggested that HGF, macrophage stimulat-
Growth factors are involved in multiple responses such ing protein (MSP; a growth factor with biological effects
as cell proliferation, differentiation, and motility mediat- similar to HGF), apolipoprotein-a, and plasminogen have
ing their effects via receptor tyrosine kinases [1, 2]. The evolved from a common ancestral gene [28, 29]. Two
type of response triggered depends on receptors and truncated variants of HGF containing the N-terminal
ligands that are differentially expressed by various cell region and the first (HGF/NK1) or the first and the
types. This review focuses on the structure, function, and second (HGF/NK2) kringle domains are generated by
alternative splicing. NK2 behaves as an HGF antagonist
[30]. NK1 is derived from a 2.2 kb transcript [4] and is
able to exhibit agonistic and antagonistic actions [30–33].
In hepatocytes, NK1 acts primarily as an HGF antagonistKey words: growth factors, HGF, cell proliferation, tumorigenesis,
nephroprotection, renotropic growth factor. [34] but elicits an agonistic response in the presence
of heparin [35]. NK1 transgenic mice reveal the typicalReceived for publication June 29, 1999
phenotype of HGF transgenic mice, underscoring its ago-and in revised form October 18, 1999
Accepted for publication November 2, 1999 nistic action in vivo [36]. A shorter synthetic HGF vari-
ant, HGF/NK4, can act as an antagonist [37].Ó 2000 by the International Society of Nephrology
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Table 1. Synopsis on biologic features of hepatocyte Table 2. Synopsis on biologic features of c-met
growth factor (HGF)
Polypeptide features of c-met
• product of the c-met proto-oncogeneSynonymous polypeptides
• fibroblast tumor cytotoxic factor (F-TCF) • synonymous polypeptides not known
• 190 kD precursor• hepatocyte growth factor (HGF)
• hepatopoietin A • N-glycosylated mature protein
• two disulfide-linked subunits• hepatotropin
• scatter factor (SF) a-chain, 50 kD, extracellular location
b-chain, 145 kD, extracellular, transmembrane and intracellularRelated polypeptides
• apolipoprotein (a) two major isoforms differing by a 47-aa segment in the juxta-
membrane domain• blood coagulation factor XIIa
• macrophage-stimulating protein (MSP) single noninterrupted tyrosine kinase domain in the b-chain
Related polypeptides• plasminogen
Biologic effects • Ron tyrosine kinase receptor (ligand MSP)
• Sea tyrosine kinase receptor• mitogen
• morphogen c-met gene localization
• human chromosome 7, bands 7q21-q23• motogen
• inductor of tubulogenesis Biologic function
• receptor unique for HGF• promotor of invasiveness
HGF gene localization c-met expression
• almost all epithelia (e.g., kidney, liver, stomach, small intestine,• human chromosome 7, bands 7q11.2-q21
Polypeptide characteristics brain, breast)
• endothelial cells• monomeric inactive precursor (pro-HGF)
• heterodimeric form (a/b-chain) after proteolytic cleavage (728 aa) • increased expression in several carcinoma
• various isoforms (truncation, alternative splicing)
• four kringle domains
• one inactive serine protease domain
• four potential glycosylation sites
• heparin and glycosaminoglycans binding sites A specific Tyr at position 1356 in the C-terminal tail is
HGF expression
needed for cell motility and morphogenesis [57]. Heparin• during organ development (e.g., kidney, liver, trophoblast)
• in adult life in tissue of mesodermal origin (e.g., fibroblasts, blood or similar extracellular matrix compounds can modulate
mononuclear cells, platelets) HGF binding and action [58, 59]. Heparin-like molecules
can stabilize HGF oligomers and enhance the mitogenic
potency, probably by facilitating c-met receptor dimer-
ization and activation [60], whereas heparan sulfate pro-
HEPATOCYTE GROWTH FACTOR RECEPTOR teoglycans act as negative modulators [61].
BINDING AND SIGNALING
The HGF receptor is the product of the c-met proto-
EXPRESSION OF HEPATOCYTE GROWTHoncogene [38]. A synopsis on the biological features of
FACTOR AND c-met AND BIOLOGICAL EFFECTSc-met is given in Table 2. The c-met product is a tyrosine
Hepatocyte growth factor is expressed in tissues ofkinase receptor [39–43] with two disulfide-linked sub-
mesodermal origin [62], whereas c-met is expressed inunits and a single noninterrupted kinase domain sharing
epithelia, including liver and kidney [63], and in severalhomology with the src family of tyrosine kinases (Fig. 1).
human carcinomas [64]. Steroid hormones, cytokines [tu-The c-met tyrosine protein kinase oncogene family is
mor necrosis factor-a (TNF-a), interleukin (IL)-1, IL-6],related to cell invasiveness and comprises v-ros, the insu-
and basic fibroblast growth factor (bFGF) regulate HGFlin-like growth factor (IGF)-I receptor, the 220 kD SEX
and c-met expression [5, 65, 66]. According to the find-protein, Ron (MSP receptor), and Sea (sarcoma, erythro-
ings in double transgenic HGF/transforming growth fac-blastosis, and anemia; unknown ligand) [44–49]. Ron and
tor (TGF)-a mice, HGF produces a partially inhibitorySea can induce the same biological effects as c-met [47].
effect on hepatocellular carcinogenesis induced by TGF-aAfter HGF binding and subsequent ligand-induced re-
[67]. Furthermore, HGF can reverse the arrest on cellceptor dimerization, c-met is activated by autophosphory-
growth induced by TGF-b [68], whereas TGF-b waslation (Fig. 1A) [16, 39, 41, 43, 50–52]. The principal site
shown to enhance the motogenic effects of epidermalfor autophosphorylation is located in the kinase domain
growth factor (EGF) but not HGF [69]. EGF can nega-at Tyr 1235, which together with Tyr 1230 and Tyr 1234,
tively modulate HGF-induced cell migration [70]. In con-comprises a common “three tyrosine” motif that is con-
trast, the HGF-induced increase in DNA synthesis inserved in the insulin and platelet-derived growth factor
hepatocytes of HGF-transgenic mice is intensified by(PDGF) receptor tyrosine kinases [53]. The phosphory-
EGF or insulin, and the growth inhibitory effects oflation of Ser 985 [54] and a protein phosphatase [55] can
TGF-b are depressed [71].negatively modulate c-met kinase activity. Experiments
Besides its renotropic action (vide infra), HGF exertswith receptor chimeras showed that c-met is the first
downstream effector in the HGF signaling cascade [56]. pleiotropic biological effects on different cell types. At
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Table 3. Role of HGF/c-met in kidney
Organogenesis
• HGF or c-met knockout mice die in utero before any kidney
abnormality appears
In vitro effects
• increase of DNA synthesis in kidney epithelial cells
• scattering
• invasiveness in collagen cells
In vivo effects
• promotes the recovery of renal function after
ischemia
unilateral nephrectomy
chemical-induced renal damage
In human kidney disease
• mutations in c-met are associated with hereditary papillary renal
carcinoma
• c-met is increased in most of the renal carcinomas
• possible link between HGF overexpression and renal cysts
• possible association between c-met up-regulation and diabetic
renal hypertrophy
least some of the biological effects of HGF are due to
inhibition of apoptosis [72, 73]. HGF is a potent mitogen
for hepatocytes and is crucial for liver development [74–
76]. Transgenic mice expressing HGF under the control
of the albumin promoter performed liver regeneration
two times faster than normal mice [77], whereas tumors
of diverse origin were found in HGF transgenic mice
under the control of the metallothionein promoter [78].
On the other hand, in c-myc/HGF double transgenic
mice, hepatic tumorigenesis induced by c-myc is pre-
vented by HGF [79]. HGF-expressing fibroblasts prevent
the onset of acute liver damage induced by CCl4 or bacte-
rial lipopolysaccharide when transplanted into the spleen
of rats [80]. Elevated HGF levels have been reported
after partial liver resection, acute or chronic hepatitis,
and fulminant liver failure [81, 82]. In acute hepatitis,
serum HGF levels are approximately twofold higher
compared with controls [83].
HEPATOCYTE GROWTH FACTOR, c-met, AND
THE KIDNEY
Fig. 1. Molecular structure of the hepatocyte growth factor (HGF)
The role of HGF and c-met in the kidney is summa-receptor c-met (A) and signal transduction (B). (A) The c-met product
(left) is a tyrosine kinase receptor of 190 kD with two disulfide-linked rized in Table 3. During perinatal kidney development
subunits, a 50 kD extracellular a-chain (a) and a 145 kD b-chain (b). in rats, diverse receptor tyrosine kinases and growthHGF binding induces receptor dimerization (middle) and autophosphory-
factors are expressed or activated including c-met andlation (right). (B) After autoposphorylation in the kinase domain of c-
met (Tyr1234, Tyr1235; indicated as Y in the white box), a downstream HGF [84]. In mouse metanephros at embryonic day 11,
located multifunctional docking site (Tyr1349, Tyr1356) in the C-terminal
HGF is expressed primarily in the mesenchyme, whereasdomain mediates the signal to multiple transducers, including PI3 ki-
nase, the Grb2/Sos/Ras complex, the IRS-like multiadaptor protein c-met is found also in the ureteric bud [85]. An important
Gab-1, phospholipase-g, and probably Src. The pleiotropic effects of role of HGF during branching morphogenesis of the
HGF are mediated via different signaling pathways, which may differ
ureteric bud has been suggested by several cell culturein various cell types.
studies [85, 86]. HGF stimulates epithelial differentiation
of metanephric mesenchymal cells [87]. The formation
of HGF/SF-induced branching tubules in MDCK cells
cultured in collagen gels is connected with the induction
of membrane type 1 matrix metalloproteinase [88]. At
Vargas et al: HGF in renal failure 1429
ing is based on the ability of HGF to inhibit junctional
communications, to enhance proteolysis of connexin 43
[96], and to change the phosphorylation patterns of junc-
tional molecules, thereby increasing their stability [97].
In MDCK cells transformed with SV40 large T antigen,
scattering is specifically triggered via inactivation of reti-
noblastoma protein inducing an HGF autocrine loop
[98]. In renal epithelial cells, the ectopic overexpression
of HGF is able to up-regulate the level of c-met and to
stimulate cell scattering [99].
The pleiotropic effects of HGF are mediated via differ-
ent signaling pathways, which may show differences in
various cell types. In all cases, a multifunctional docking
site (Tyr at position 1349 and 1356 in the C-terminal
domain) mediates the signal of activated c-met receptors
to multiple transducers (Fig. 1B), including PI3 kinase,
the Grb2/Sos/Ras complex, the insulin receptor substrate
(IRS)-like multiadaptor protein Gab-1, and probably Src
[100–102]. It is important to note that c-met–mediated
biological effects can be dissected on the basis of differ-
ent signaling requirements [100]. In MDCK cells, HGF-
induced cell scattering is dependent on the Ras–mitogen-
activated protein kinase (MAPK) signaling pathway
[103]. In rabbit proximal renal tubular cells, we demon-
strated that the growth-promoting effects of HGF in-
volve the activation of Src, whereas the HGF-induced
tubulogenic differentiation (for example, formation of
long microvilli at the apical cell membrane) was notFig. 2. Morphogenic effects of HGF on cultured proximal tubular cells.
The differentiated rabbit proximal tubular cell line PT-1 was cultured influenced by src-interfering tyrosine kinase inhibitors
in Dulbecco’s modified Eagle’s medium (DMEM) as described [94, 95]. [95]. Invasive cell growth upon stimulation of c-met re-
Cells were incubated for 48 hours in serum-free medium alone (A; bar 5
quires the concomitant activation of Ras and PI-3 kinase10 mm) or in the presence of HGF (1029 mol/L; B). HGF induced cell
scattering (thin arrows) and tubulogenesis (thick arrows). Reprinted [49] or Src and PI3 kinase [104]. Scattering needs PI3-
with permission from Jehle et al [94]. kinase activation [105–107] and in some cell types also
requires an additional effector [108]. Morphological
changes induced by HGF in MDCK cells are related to
modifications in cell polarity with alteration of synthesisthe first stages of kidney tubulogenesis, other growth fac-
rate and interaction between b-catenin and E-cadherintors may replace the morphogenetic role of HGF. c-met
[109]. The cell spreading response in this model is depen-knockout kidney cells form tubules in vitro upon stimula-
dent on the activation of the small guanine 59-triphos-tion with TGF-a [89]. Another study showed that TGF-a
phate (GTP)-binding proteins Ras and Rac. PI3 kinaseand EGF induce tubulogenesis of murine inner medul-
is also involved in mediating the effects of HGF on tubu-lary collecting duct cells [90]. Coculture experiments re-
logenesis [110]. In MDCK cells, HGF-induced tubulo-vealed that HGF produced by mesangial cells stimulates
genesis and branching are enhanced by several compo-endothelial cell growth and that this interaction is nega-
nents of the cell matrix, such as laminin, fibronectin, andtively modulated by TGF-b and angiotensin II [73].
entactin, but are inhibited by type IV collagen, heparanThese authors suggested that negative regulation of local
sulfate proteoglycan, vitronectin, and TGF-b [111]. InHGF production by both factors may play an important
these cells, the branching development is regulated byrole in the pathogenesis of renal disease.
phosphorylation processes mediated by protein kinase AThe morphogenetic and motogenic effects of HGF
(PKA), protein kinase C (PKC), and Ca21/calmodulin-were first described in the MDCK cell line [91] and were
dependent kinases [111]. Another protein involved inconfirmed in a variety of other epithelial cells [92–94].
the scattering and tubulogenesis mediated by HGF inIn differentiated rabbit proximal tubular cells, HGF ex-
kidney cells is the membrane-cytoskeleton linker ezrin,hibits potent mitogenic, morphogenetic, motogenic, and
which is phosphorylated by c-met [112]. Downstream ofepithelial cell-differentiating effects under serum-free
Grb2 [106], the tubulogenic HGF response is dependentconditions [95]. Among its pleiotropic effects, the induc-
tion of cell scattering plays a pivotal role (Fig. 2). Scatter- on the STAT pathway [113].
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nephrectomy or partial hepatectomy [118]. An increase
of HGF and its mRNA was also detected in rats after
unilateral nephrectomy and CCl4 treatment, with con-
comitant internalization of c-met [119], and a transient
increase of HGF precedes the regenerating events in rat
kidney after vitamin E depletion combined with glutathi-
one depletion [120]. HGF and HGF mRNA increase in
rat kidney after ischemia or HgCl2-induced nephrotoxic-
ity and levels remain augmented during the phase of
tubular regeneration [121]. On the other hand, the renal
expression of c-met increases in rats after ischemia, uni-
lateral nephrectomy, or folic acid treatment [122]. A link
between renal hypertrophy observed in diabetic rats was
Fig. 3. Stimulation of c-met gene expression by cytokines and growth also proposed in relationship with the elevation of c-metfactors in cultured renal epithelial cells. Mouse inner medullary collect-
in medullar and cortical tubular epithelium [123]. Aing duct epithelial cells (mIMCD-3) were incubated for 24 hours in
serum-free medium without (control) or with specific cytokines or spontaneous mouse model of chronic renal disease [im-
growth factors at a concentration of 10 ng/mL. The total cellular RNA mune complex glomerulonephritis (ICGN) strain devel-was isolated and hybridized using rat c-met cDNA as a probe. The
oping glomerular sclerotic injury, tubular atrophy, andsame blot was stripped and reprobed with GAPDH to confirm equal
loading of the RNA. Similar results were obtained using proximal renal dysfunction until 17 weeks of age] was used to
tubule-derived opossum kidney epithelial cells. Reprinted with permis- investigate whether HGF may inhibit the progression ofsion from Liu et al [116].
tubulointerstitial fibrosis [124]. When recombinant HGF
was injected into these mice during a four-week period
(from weeks 14 through 17 after birth), DNA synthesis
of tubular epithelial cells was found to be 4.4-fold higher
Evidence that HGF may represent an important reno- than in mice without HGF injection, thereby suggesting
tropic growth factor came from cell culture studies, ani- tubular parenchymal expansion promoted by HGF. No-
mal experiments, and findings in human kidney disease. tably, HGF suppressed the expression of TGF-b and of
HGF promotes DNA synthesis of several renal cell types, PDGF as well as myofibroblast formation in the affected
including tubular and glomerular epithelial cells [94, 114, kidney. Consequently, HGF completely inhibited the on-
115]. The mitogenic effects of HGF on renal tubular set of tubulointerstitial fibrosis and attenuated the pro-
epithelial cells are regulated by cell–cell interactions [114]. gression of glomerulosclerosis, both preventing manifesta-
DNA synthesis stimulated by HGF was high at a low cell tion of renal dysfunction. From these results, supplement
density and was strongly suppressed at a higher one. These therapy with HGF may be taken into consideration as a
results suggest that HGF may act not only as an inductor, novel option for prevention and treatment of chronic
but also as a modulator in renal regeneration and com- renal disease.
pensatory renal growth. In conditions of renal injury medi- Increased HGF mRNA transcripts were detected in
ated by folic acid treatment, HGF up-regulates c-met in mesenchymal and tubular epithelial cells of rejecting kid-
a tissue-specific manner, acting primarily at the transcrip- ney [125], and elevated serum HGF levels were sug-
tional level by stimulating the c-met promoter activity [116]. gested to indicate renal rejection [126]. Serum HGF lev-
This study also demonstrated up-regulation of c-met ex- els correlate with serum creatinine in chronic renal
pression in renal epithelial cells in vitro by interleukins, failure patients, indicating a response to the organ dam-
TGF-b, EGF, insulin-like growth factors (IGFs), and age or decreased clearance by the insufficient kidney.
platelet-derived growth factor (PDGF) (Fig. 3). Because In acute renal failure, elevated urine HGF levels are
tissue regeneration results from the integration of the described as consistent with a role for HGF in promoting
complex interplay among many different growth factors, tubule cell proliferation [127], whereas patients with
c-met seems to be at a convergence point and may play chronic glomerular or polycystic disease, as well as pa-
a key role in the processes leading to the completion of tients with advanced chronic renal insufficiency and
the entire regenerative course. In the adult mouse kid- healthy controls, show detectable but low urine HGF
ney, in situ hybridization experiments localized c-met in levels [127, 128]. Hemodialysis with cellulosic or biocom-
proximal and distal tubules [63]. During experimental patible membranes and with or without heparin stimu-
acute renal failure, elevated HGF mRNA levels were lates the increase of HGF levels in circulation, and serum
found in kidney and liver, but c-met mRNA was up- of dialysis patients induces the HGF production in mono-
regulated selectively at the site of greatest tubular injury nuclear cells and fibroblasts [129]. HGF was also detected
or hypertrophy [117]. HGF mRNA and peptide levels in cyst fluids in cases of renal cystic disease, suggesting
a possible causal coherence with this pathology [130]. Fur-increases in kidney and spleen in response to unilateral
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sion. In hepatic nonparenchymal cell lines, HGF trans-
fection produces a loss of cell contact inhibition and the
generation of large, invasive tumors in nude mice [134].
Hepatocyte cell lines expressing HGF display the same
characteristics [133]. In fibroblasts, simultaneous expres-
sion of HGF and c-met is required for tumorigenesis
[135]. Bladder carcinoma cells exhibit a scattered pheno-
type when transfected with HGF and are more invasive
than untransfected cells [136]. In renal carcinogenesis,
c-met plays a role as an inductor of invasiveness. In 87%
of renal carcinomas and in one renal carcinoma cell line,
c-met was detected [137]. In SMTK-R3, another renal
carcinoma cell line, HGF stimulates not only cell motility
and proliferation, but also the glycolipid sulfotransfer-
ases activity, indicating multiple biological effects in re-
nal cell carcinomas [138]. In this context, several reports
suggested a relationship between the human hereditary
papillary renal carcinoma and mutations in the tyrosine
kinase domain of c-met [100]. In contrast, both HGF
and c-met mRNA levels are normal in nephroblastomas
[139]. Abnormal overexpression of HGF produces mes-
enchymal and epithelial tumors in mice with c-met acti-
vation by an autocrine loop [140].
The role of HGF/c-met in tumor progression may be
explained in part by an association of the multifunctional
docking site of c-met (Fig. 1B) with the anti-apoptotic
protein BAG-1 and other substrates [141, 142]. In oral
squamous carcinoma cell lines, HGF acts as a promoter
of cell migration and invasion with tyrosine phosphoryla-Fig. 4. Endothelin-1 release by cultured proximal tubular (PT-1) cells,
coincubated with cyclosporine A and hepatocyte growth factor (HGF, tion of p125FAK kinase [143]. In contrast to these data,
1028 mol/L) or epidermal growth factor (EGF, 1028 mol/L). Data are the antiproliferative effects of HGF were described inmeans 6 SEM, N 5 6. ***P , 0.001 vs. cyclosporine 50 mg/L; 111P ,
melanoma, squamous carcinoma, and hepatocellular car-0.001 vs. cyclosporine 500 mg/L. Reprinted with permission from Haug
et al [132]. cinoma cell (HCC) lines [144]. The introduction of an
HGF vector in HCCs inhibits cell growth in vitro and
diminishes tumor growth in vivo, but stimulates growth
of normal hepatocytes [145]. Growth inhibition and in-
duction of apoptosis by HGF have been shown also inthermore, HGF may be involved in the pathogenesis of
transformed rat liver epithelial cells [146].inflammatory renal diseases. Rat mesangial cells coexpress
HGF and c-met in response to IL-6 stimulation in vitro
[131]. In cultured renal proximal tubular cells, we showed DIAGNOSTIC AND THERAPEUTIC
that HGF potently inhibits the cyclosporine A- or tacroli- IMPLICATIONS OF HGF/c-met IN
mus-induced endothelin-1 release (Fig. 4) [132]. Taken KIDNEY DISEASES
together, the above-mentioned studies indicate that HGF,
A plethora of clinical applications for treatment withdespite its activity on promoting renal regeneration in
HGF or HGF analogue peptides might be raised in theacute processes, may also be involved in the development
near future [147]. Clinical indications for HGF treatmentof histologic changes associated with the loss of kidney
were suggested in kidney, liver, and lung regeneration,functionality in chronic diseases.
as well as in the treatment of diabetes mellitus, gastric
ulcers, and vascular or neuroneal diseases [147]. A recent
HEPATOCYTE GROWTH FACTOR, c-met, AND report describes the reversion of liver cirrhosis in rats
TUMOR CELL GROWTH injected with an HGF expression vector [148]. Reports
connect the severity of arterial hypertension with signifi-Hepatocyte growth factor and c-met are involved in
cantly increased circulating HGF levels, probably as amalignant cell growth. HGF transforms immortalized
consequence of endothelial cell damage [149]. A markedmouse epithelial cells [133], and several lines of evidence
suggest that its scatter ability is critical in tumor progres- elevation of HGF serum levels could also be found in
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the first stages of myocardial infarction but not in other thesis in tubular epithelial cells, attenuates glomerulo-
sclerosis, and inhibits almost totally the development ofheart diseases [150]. Thus, HGF may be used as a serum
marker to monitor the course of myocardium infarction tubulointerstitial fibrosis [124]. In contrast, transgenic
mice expressing HGF under control of the metallothio-and hypertension-induced endothelial dysfunction. In di-
verse neoplastic diseases, HGF and/or c-met were also nein promoter develop glomerulosclerosis, tubular hy-
perplasia, and polycystic kidney disease [154]. The sameproposed as novel clinical markers of diagnostic or prog-
nostic value. Probably the most exciting possibilities of animals show also a marked incidence of tumors of di-
verse origin [140], probably because of the systemic over-the clinical utilization of HGF and/or c-met are related
to therapy with two basic variants: HGF or c-met block- expression of HGF. In fact, in the less affected metallo-
thionein-HGF mice line, the severity of kidney diseaseade in proliferative diseases or HGF-induced tissue re-
generation [147]. Protocols including the preadministra- is not correlated to the HGF level in serum, but to the
liver weight. These findings were interpreted as a contri-tion of HGF to prevent nephrotoxic side effects of drugs
or to induce restoration of functional integrity in diverse bution of the liver hypertrophy and the systemic HGF
tissues after surgical manipulation may be of clinical levels to the onset of kidney disease in these animals.
relevance. Finally, our comprehension of the factors involved in
Several experimental models indicate a possible thera- the subtle equilibrium between HGF-induced cell and
peutic application of HGF in kidney diseases. In animal organ regeneration and tumorigenesis is still incomplete,
models, HGF is at least as potent as EGF or IGF-1 to and several problems have to be solved before consider-
recover the renal function after acute injury [121, 151]. ing HGF as a therapeutical agent in human kidney dis-
The administration of HGF accelerates recovery from ease. The short half-life and fast clearance of HGF from
acute ischemic renal injury in rats by enhancing regener- circulation may be overcome by HGF variants with a
ation of proximal tubular epithelium [152]. In this study, longer life in circulation [61]. However, the use of such
the beneficial effects of HGF on the clinical outcome agents may be limited by enhanced systemic side-effects.
are indicated by significantly lower creatinine and blood A therapeutical challenge for the future could be the
urea nitrogen levels, enhanced insulin clearances, re- design of tissue-specific vectors to express HGF in dam-
duced mortality, and much less injury in kidney histolog- aged organs, most importantly in kidney during acute
ies. Furthermore, the administration of HGF may even renal failure. This could be an approach to avoid the
prevent acute renal failure when given in a prophylactic deleterious consequences of systemic HGF expression
manner [121]. HGF not only activates tubular repair [140] and to use the amazing biological potency of this
processes but also ameliorates the initial injury (for ex- renotropic growth factor.
ample, cisplatin toxicity) by protecting renal epithelial
cells from undergoing apoptosis [72]. It is important, ACKNOWLEDGMENTS
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